Literature DB >> 15256058

Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.

Paola Secchiero1, Arianna Gonelli, Edvige Carnevale, Federica Corallini, Clara Rizzardi, Serena Zacchigna, Mauro Melato, Giorgio Zauli.   

Abstract

Starting from the observation that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L protein is expressed in both malignant and inflammatory cells in some highly vascularized soft tissue sarcomas, the angiogenic potential of TRAIL was investigated in a series of in vitro assays. Recombinant soluble TRAIL induced endothelial cell migration and vessel tube formation to a degree comparable to vascular endothelial growth factor (VEGF), one of the best-characterized angiogenic factors. However, the proangiogenic activity of TRAIL was not mediated by endogenous expression of VEGF. Although TRAIL potentiated VEGF-induced extracellular signal-regulated kinase (ERK) phosphorylation and endothelial cell proliferation, the combination of TRAIL + VEGF did not show additive effects with respect to VEGF alone in inducing vessel tube formation. Thus, although TRAIL has gained attention as a potential anticancer therapeutic for its ability to induce apoptosis in a variety of cancer cells, our present data suggest that TRAIL might also play an unexpected role in promoting angiogenesis, which might have therapeutic implications. Copyright 2004 Neoplasia Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256058      PMCID: PMC1502116          DOI: 10.1593/neo.03421

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  38 in total

Review 1.  The TNF and TNF receptor superfamilies: integrating mammalian biology.

Authors:  R M Locksley; N Killeen; M J Lenardo
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types.

Authors:  X D Zhang; T Nguyen; W D Thomas; J E Sanders; P Hersey
Journal:  FEBS Lett       Date:  2000-10-06       Impact factor: 4.124

Review 3.  Angiogenesis in health and disease.

Authors:  Peter Carmeliet
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

4.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

Authors:  A Passaniti; R M Taylor; R Pili; Y Guo; P V Long; J A Haney; R R Pauly; D S Grant; G R Martin
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

5.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

6.  Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase.

Authors:  S Rousseau; F Houle; H Kotanides; L Witte; J Waltenberger; J Landry; J Huot
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

7.  Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt.

Authors:  M Morales-Ruiz; D Fulton; G Sowa; L R Languino; Y Fujio; K Walsh; W C Sessa
Journal:  Circ Res       Date:  2000-04-28       Impact factor: 17.367

8.  The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma.

Authors:  T Mentzel; L F Brown; H F Dvorak; C Kuhnen; K J Stiller; D Katenkamp; C D Fletcher
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

9.  TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.

Authors:  Paola Secchiero; Arianna Gonelli; Edvige Carnevale; Daniela Milani; Assunta Pandolfi; Davide Zella; Giorgio Zauli
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

Review 10.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

View more
  20 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

Review 3.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

4.  Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern.

Authors:  Ozlem Darcansoy Işeri; Meltem Demirel Kars; Ufuk Gündüz
Journal:  Mol Biol Rep       Date:  2011-07-01       Impact factor: 2.316

5.  Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma.

Authors:  Xiuru Ma; Xiaoming Li; Xiuying Lu; Lifeng Jia; Hui Li; Qi Song
Journal:  Tumour Biol       Date:  2015-06-27

Review 6.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

7.  Pim protein kinase-3 is regulated by TNF-α and promotes endothelial cell sprouting.

Authors:  Handong Yang; Yinfang Wang; Hang Qian; Peng Zhang; Congxin Huang
Journal:  Mol Cells       Date:  2011-08-23       Impact factor: 5.034

8.  TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Authors:  Suizhao Wang; Wenhong Ren; Jeffery Liu; Guy Lahat; Keila Torres; Gonzalo Lopez; Alexander J Lazar; Andrea Hayes-Jordan; Kebin Liu; Jim Bankson; John D Hazle; Dina Lev
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

9.  The Naïve Murine Cornea as a Model System to Identify Novel Endogenous Regulators of Lymphangiogenesis: TRAIL and rtPA.

Authors:  Birgit Regenfuß; Marie-Luise Dreisow; Deniz Hos; Sharmila Masli; Felix Bock; Claus Cursiefen
Journal:  Lymphat Res Biol       Date:  2015-06       Impact factor: 2.589

10.  Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.

Authors:  Liangran Guo; Li Fan; Jinfeng Ren; Zhiqing Pang; Yulong Ren; Jingwei Li; Ziyi Wen; Yong Qian; Lin Zhang; Hang Ma; Xinguo Jiang
Journal:  Int J Nanomedicine       Date:  2012-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.